ADIL - エ―ダイヤル・ファ―マシュ―ティカルズ （Adial Pharmaceuticals Inc） エ―ダイヤル・ファ―マシュ―ティカルズADILのチャート
ADILの企業情報
| symbol | ADIL |
|---|---|
| 会社名 | ADial Pharmaceuticals Inc （エ―ダイヤル・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a therapeutic agent for the treatment of alcohol use disorder (AUD). Its lead drug product is AD04. AD04 is a selective serotonin-3 antagonist. AD04 can also be used for the treatment of other addictive disorders such as obesity smoking and drug addiction. The Company has completed a Phase-II clinical trials of AD04. エ―ダイヤル・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、アルコ―ル依存症などアルコ―ルの使用障害に対する治療薬の開発に従事する。同社の主力製品に、吐き気や嘔吐の治療に有効な選択的セトロニン3拮抗薬である「AD04」を含む。本社所在地はバ―ジニア州シャ―ロッツビル。 Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. |
| 本社所在地 | 1180 Seminole Trail Suite 495 Charlottesville VA 22902 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 434-422-9800 |
| 設立年月日 | 40483 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.adialpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/adil |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -2.66463 |
| 終値（lastsale） | 2.72 |
| 時価総額（marketcap） | 17783969.28 |
| 時価総額 | 時価総額（百万ドル） 19.40650 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 20.25449 |
| 当期純利益 | 当期純利益（百万ドル） -2.86793 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Adial Pharmaceuticals Inc revenues was not reported. Net loss increased from $443K to $2.2M. Higher net loss reflects General and Administrative Expenses increase of 35% to $417K (expense) Interest Expense increase from $32K to $103K (expense) Research and development expenses increase of 29% to $132K (expense). |
ADILのテクニカル分析
ADILのニュース
Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate 2022/09/26 16:43:37 Benzinga
Adial Pharmaceuticals Inc''s (NASDAQ: ADIL ) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not … Full story available on Benzinga.com
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain 2022/09/26 13:00:00 GlobeNewswire
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 significantly reduced pain compared to both placebo and acetaminophen
Volume - Adial Pharmaceuticals, Inc. Short Interest Update 2022/09/19 08:05:09 Business Mag
Adial Pharmaceuticals, Inc. was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 335,900…
Adial Pharmaceuticals names new executive chief 2022/08/22 20:37:25 Seeking Alpha
Adial Pharmaceuticals (ADIL) appoints Cary J. Claiborne as President and CEO. Mr
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer 2022/08/22 20:30:00 GlobeNewswire
Kevin Schuyler appointed Chairman of Adial’s Board
Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate 2022/09/26 16:43:37 Benzinga
Adial Pharmaceuticals Inc''s (NASDAQ: ADIL ) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not … Full story available on Benzinga.com
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain 2022/09/26 13:00:00 GlobeNewswire
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 significantly reduced pain compared to both placebo and acetaminophen
Volume - Adial Pharmaceuticals, Inc. Short Interest Update 2022/09/19 08:05:09 Business Mag
Adial Pharmaceuticals, Inc. was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 335,900…
Adial Pharmaceuticals names new executive chief 2022/08/22 20:37:25 Seeking Alpha
Adial Pharmaceuticals (ADIL) appoints Cary J. Claiborne as President and CEO. Mr
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer 2022/08/22 20:30:00 GlobeNewswire
Kevin Schuyler appointed Chairman of Adial’s Board
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH 2022/05/19 13:25:00 GlobeNewswire
CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing novel molecules targeting the adenosine receptors for the treatment of major unmet medical needs, has entered into a research collaboration with the Medical College of Wisconsin , a leading medical school, and Dr. John Auchampach, PhD , Professor and Vice Chair of the Department of Pharmacology and Toxicology. The goal of the collaboration is to further evaluate the Company’s proprietary adenosine analogs as potential treatments for diabetes and non-alcoholic steatohepatitis (NASH). NASH is the most severe form of non-alcoholic fatty liver disease involving liver inflammation (hepatitis) that can lead to life-threatening cardiovascular co-morbidities.
Adial Pharmaceuticals GAAP EPS of -$0.13 beats by $0.04 2022/05/16 13:37:36 Seeking Alpha
Adial Pharmaceuticals press release (ADIL): Q1 GAAP EPS of -$0.13 beats by $0.04.As of March 31, 2022, cash and cash equivalents were $12.7 million as compared to $6.1 million as…
Adial Pharmaceuticals reports Q1 results 2022/05/16 13:32:25 Seeking Alpha
Adial Pharmaceuticals press release (ADIL): Q1 GAAP EPS of -$0.13 beats by $0.04.As of March 31, 2022, cash and cash equivalents were $12.7M vs. $6.1M as of Dec
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results 2022/05/16 13:25:00 GlobeNewswire
Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate''s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders 2022/05/04 13:15:00 Benzinga
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL , ADILW)) ("Adial" or the "Company"), today announced that Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major unmet medical needs, has entered into a research collaboration agreement with the University of California San Diego (UC San Diego), a leading education and research university, and Dr. Peter Ernst, DVM, PhD , Professor of Pathology and an expert in the fields of immunology, inflammation and infectious disease, to further evaluate the Company''s proprietary adenosine analogs as a potential treatment for inflammatory diseases, including inflammatory bowel disease (IBD) and infectious diseases where a large immune response (i.e., cytokine storm) plays a significant role. Under the collaboration agreement, Dr. Ernst and his team will initially test Purnovate''s adenosine compounds in non-clinical models of IBD with the goal of further validating the potential of Purnovate''s compounds as a treatment for IBD.